NMPA Approves Hengrui’s Ruitanning (Fosrolapitant/Palonosetron) for Moderately Emetogenic Chemotherapy – China’s First Ultra‑Long‑Acting Dual‑Target Antiemetic

Fineline Cube
4 Min Read
Summarize with AI

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) (SHA: 600276; HKG: 1276) announced that its fosrolapitant and palonosetron for injection (trade name: Ruitanning) has been approved by China’s National Medical Products Administration (NMPA) for a new indication: the prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC) in adult patients — extending the product’s footprint beyond its 2025 highly emetogenic chemotherapy (HEC) approval.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyNational Medical Products Administration (NMPA), China
Approval TypeNew indication approval
ProductFosrolapitant and palonosetron for injection (trade name: Ruitanning)
New IndicationPrevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC) in adult patients
Prior Approval2025 – prevention of acute and delayed chemotherapy‑induced nausea and vomiting (CINV) induced by highly emetogenic chemotherapy (HEC) in adults
Supporting TrialPROTECT study (HR20013‑302) – multicenter, randomized, double‑blind, active‑controlled Phase III

Drug Profile & Mechanism of Action

  • Product Positioning: China’s first ultra‑long‑acting, independently developed dual‑target antiemetic injection for chemotherapy‑induced nausea and vomiting (CINV).
  • NK‑1 Component: Fosrolapitant is converted in the body to rolapitant, which blocks the NK‑1 receptor‑mediated signaling pathway in the vomiting center — the central driver of delayed emesis.
  • 5‑HT3 Component: Palonosetron blocks the 5‑HT3 receptor‑mediated peripheral vomiting signaling pathway, controlling acute emesis.
  • Dual‑Target Synergy: Simultaneous central NK‑1 and peripheral 5‑HT3 blockade in a single fixed‑dose injection addresses both acute and delayed phases of CINV, with ultra‑long‑acting pharmacology designed to cover the full risk window after chemotherapy.

Clinical Evidence – PROTECT Study (Phase III)

Endpoint (Delayed Phase)Ruitanning + DexamethasonePalonosetron + DexamethasoneRelative Benefit
Complete Response Rate79.0 %61.4 %+17.6 ppt
SafetySimilar profile; no new safety signalsSimilar profileComparable tolerability

The approval of the new indication is based on the PROTECT study (HR20013‑302), a multicenter, randomized, double‑blind, active‑controlled Phase III clinical trial. In the delayed phase, the complete response rate in the Ruitanning (fosrolapitant and palonosetron for injection) plus dexamethasone group was significantly higher than in the palonosetron plus dexamethasone active‑control group (79.0 % vs. 61.4 %). The safety profiles of the two groups were similar, and no new safety signals were observed in the study.

Market Impact & Outlook

  • CINV Landscape: Nausea and vomiting remain among the most feared side effects of chemotherapy; MEC regimens affect a broad patient population in which delayed emesis is frequently under‑controlled by 5‑HT3‑only therapy.
  • Indication Expansion: Adding MEC to the prior HEC label substantially widens Ruitanning’s addressable patient pool across the emetogenic‑risk spectrum in China.
  • Competitive Edge: As an ultra‑long‑acting, dual‑target fixed‑dose injection, Ruitanning offers convenience and full‑phase coverage versus multi‑drug regimens combining separate NK‑1 and 5‑HT3 agents.
  • Domestic Innovation: The product’s independent development underscores the maturation of China’s supportive‑care oncology innovation, reducing reliance on imported antiemetic combinations.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market adoption and potential label expansion of Ruitanning (fosrolapitant and palonosetron for injection). Actual results may differ materially due to risks inherent in commercial launch, reimbursement negotiations, competitive dynamics and regulatory developments.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *